Literature DB >> 11704827

Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.

N L Toomey1, V V Deyev, C Wood, L H Boise, D Scott, L H Liu, L Cabral, E R Podack, G N Barber, W J Harrington.   

Abstract

Gammaherpes viruses are often detected in lymphomas arising in immunocompromised patients. We have found that Azidothymidine (AZT) alone induces apoptosis in Epstein Barr Virus (EBV) positive Burkitt's lymphoma (BL) cells but requires interferon alpha (IFN-alpha) to induce apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL). Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and EBV-Burkitt's lines. AZT and IFN-alpha mediated apoptosis in PEL was blocked by stable overexpression of dominant negative Fas Associated Death Domain (FADD), decoy receptor 2 (DcR2), soluble TRAIL receptor fusion proteins (DR-4 and DR-5) and thymidine. Trimeric TRAIL (in place of IFN-alpha) similarly synergized with AZT to induce apoptosis in HHV-8 positive PEL cells. This is the first demonstration that IFN-alpha induces functional TRAIL in a malignancy that can be exploited to effect a suicide program. This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent a highly effective and relatively non-toxic therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704827     DOI: 10.1038/sj.onc.1204895

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Authors:  Kristopher A Sarosiek; Lucas E Cavallin; Shruti Bhatt; Ngoc L Toomey; Yasodha Natkunam; Wilfredo Blasini; Andrew J Gentles; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

3.  Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.

Authors:  Ulas Darda Bayraktar; Luis A Diaz; Brittany Ashlock; Ngoc Toomey; Lisa Cabral; Soley Bayraktar; Denise Pereira; Dirk P Dittmer; Juan Carlos Ramos
Journal:  Leuk Lymphoma       Date:  2013-08-28

Review 4.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

5.  Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma.

Authors:  Motoki Kurokawa; Subrata K Ghosh; Juan Carlos Ramos; Abdul M Mian; Ngoc L Toomey; Lisa Cabral; Denise Whitby; Glen N Barber; Dirk P Dittmer; William J Harrington
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

6.  Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.

Authors:  Abhik Datta; Marcia Bellon; Uma Sinha-Datta; Ali Bazarbachi; Yves Lepelletier; Danielle Canioni; Thomas A Waldmann; Olivier Hermine; Christophe Nicot
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

7.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

8.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients.

Authors:  E Stylianou; A Yndestad; L I Sikkeland; V Bjerkeli; J K Damås; T Haug; H G Eiken; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

10.  Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.

Authors:  Hiroki Goto; Eriko Kudo; Ryusho Kariya; Manabu Taura; Harutaka Katano; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.